The EMBRACE Study The EMBRACE Study
Randomised Controlled Study of Physical Exercise Intervention in Breast Cancer Patients at Risk of Anthracycline-induced Cardiomyopathy:The EMBRACE Study
University of Aberdeen
70 participants
Feb 1, 2020
OBSERVATIONAL
Conditions
Summary
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.
Eligibility
Inclusion Criteria3
- A patient who has been diagnosed with breast cancer and has been scheduled for a first cycle of anthracycline therapy.
- Participant who is willing and able to give informed consent for participation in the study.
- Healthy (gender and age matched) volunteers willing to give informed consent for participation in the study.
Exclusion Criteria1
- Contraindication to magnetic resonance scanning such as an implantable cardiac device.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04467411